These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24493485)

  • 1. Q: should patients with gout avoid thiazides for hypertension?
    Mandell BF
    Cleve Clin J Med; 2014 Feb; 81(2):83-6. PubMed ID: 24493485
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of asymptomatic hyperuricemia].
    Floege J
    Internist (Berl); 1997 Dec; 38(12):1233. PubMed ID: 9465329
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of gout.
    Cohen MG
    Intern Med J; 2011 Jan; 41(1a):70-1. PubMed ID: 21265967
    [No Abstract]   [Full Text] [Related]  

  • 4. Gout.
    Messerli FH; Makani H; Halpern D
    N Engl J Med; 2011 May; 364(19):1876-7; author reply 1877. PubMed ID: 21561363
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hyperuricemia and gout: therapeutic indications].
    Pawlotsky Y
    Rev Prat; 1994 Jan; 44(2):206-9. PubMed ID: 8178077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How to treat hyperuricemia and gout attacks in compensated kidney failure?].
    Gröbner W
    Dtsch Med Wochenschr; 2002 Mar; 127(11):576. PubMed ID: 11894180
    [No Abstract]   [Full Text] [Related]  

  • 7. [Attempt at normalizing the uricemia in gout].
    Piliaev VG
    Vrach Delo; 1980 Apr; (4):88-90. PubMed ID: 7385782
    [No Abstract]   [Full Text] [Related]  

  • 8. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
    Kamatani N; Hosoya T
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hyperuricemia and gout. Case report].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):207-9. PubMed ID: 11821992
    [No Abstract]   [Full Text] [Related]  

  • 10. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [GOUT AND HYPERTENSION].
    Belovol AN; Knyazkova II; Miroshnykova IA
    Lik Sprava; 2015; (1-2):32-8. PubMed ID: 26118024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease.
    Adenwalla HN; O'Connor CR
    J Clin Rheumatol; 2011 Oct; 17(7):387-8. PubMed ID: 21946469
    [No Abstract]   [Full Text] [Related]  

  • 13. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of urate-lowering therapies: managing the risks to gain the benefits.
    Keenan RT
    Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Familial gout and nephropathy in a young woman. Report of one case].
    Badilla A; Rojas C
    Rev Med Chil; 2001 Jun; 129(6):666-70. PubMed ID: 11510209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The perils of nontreatment of hyperuricemia.
    Hoffman GS
    Cleve Clin J Med; 1997 Apr; 64(4):215. PubMed ID: 9105118
    [No Abstract]   [Full Text] [Related]  

  • 18. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperuricemia: a laboratory finding needing treatment?].
    Keller C
    Verh Dtsch Ges Inn Med; 1990; 96():188-92. PubMed ID: 2092438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.